USA |NASDAQ |USD
| Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
|---|---|---|---|---|
| Nov 8, 2021 | Sep 2021 | $-0.65 | $-0.60 | $-0.70 |
| Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
|---|---|---|---|---|
| Nov 8, 2021 | Sep 2021 | $2.25M | $4.38M | $1.85M |
Fulcrum Therapeutics's next earnings date is Monday, Nov 8, 2021 for the fiscal quarter ending Sep 2021.
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 7 | $-0.80 | $-1.05 | $-0.55 |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 6 | $-2.61 | $-3.08 | $-2.27 |
| Dec 2022 | 7 | $-2.72 | $-3.41 | $-2.26 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2021 | 0 / 0 | $-0.80 | $-0.78 | $-0.80 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2021 | 0 / 0 | $-2.61 | $-2.52 | $-2.63 |
| Dec 2022 | 0 / 0 | $-2.72 | $-2.92 | $-2.79 |
| Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
|---|---|---|---|---|
| Dec 2021 | 5 | $2.35M | $0.00 | $4.00M |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 7 | $11.35M | $0.00 | $17.20M |
| Dec 2022 | 7 | $12.60M | $0.00 | $27.00M |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Nov 8, 2021 | Sep 2021 | $-0.65 | - | - |
| Aug 10, 2021 | Jun 2021 | $-0.65 | $-0.60 | 8.10% |
| May 6, 2021 | Mar 2021 | $-0.66 | $-0.54 | 17.77% |
| Mar 4, 2021 | Dec 2020 | $-0.73 | $-0.63 | 13.10% |
| Nov 10, 2020 | Sep 2020 | $-0.64 | $-0.70 | -9.80% |
| Aug 11, 2020 | Jun 2020 | $-0.75 | $-0.66 | 11.61% |
| May 13, 2020 | Mar 2020 | $-0.76 | $-0.81 | -6.58% |
| Mar 5, 2020 | Dec 2019 | $-0.88 | $-0.71 | 19.62% |
| Nov 14, 2019 | Sep 2019 | $-0.72 | $-0.97 | -34.72% |
| Aug 26, 2019 | Jun 2019 | $-0.75 | $-0.71 | 5.33% |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Mar 4, 2021 | Dec 2020 | $-2.88 | $-2.80 | - |
| Mar 5, 2020 | Dec 2019 | $-4.03 | $-2.39 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Nov 8, 2021 | Sep 2021 | $2.25M | - | - |
| Aug 10, 2021 | Jun 2021 | $1.60M | $4.38M | 2.74% |
| May 6, 2021 | Mar 2021 | $1.42M | $4.79M | 3.37% |
| Mar 4, 2021 | Dec 2020 | $1.31M | $4.22M | 3.23% |
| Nov 10, 2020 | Sep 2020 | $550.00K | $1.85M | 3.36% |
| Aug 11, 2020 | Jun 2020 | $0.00 | $2.00M | - |
| May 13, 2020 | Mar 2020 | $0.00 | $750.00K | - |
| Mar 5, 2020 | Dec 2019 | $0.00 | $0.00 | - |
| Nov 14, 2019 | Sep 2019 | $0.00 | $0.00 | - |
| Aug 26, 2019 | Jun 2019 | $0.00 | $0.00 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Mar 4, 2021 | Dec 2020 | $5.69M | $8.82M | 55.06% |
| Mar 5, 2020 | Dec 2019 | $0.00 | $0.00 | - |
FULC's next earnings date is Monday, Nov 8, 2021 for the fiscal quarter ending Sep 30, 2021.
According to 7 analysts, the average EPS estimation for Fulcrum Therapeutics's next quarterly earnings is $-0.65, with a low EPS estimation of $-0.74, and a high estimation of $-0.57.
Over the last 1 month, EPS estimates have seen 0 upward revisions and 0 downward. The EPS 1 month trend is $-0.65, the last 2 month trend is $-0.63, and the 3 month trend is $-0.65.
Based on 6 analysts, the average revenue estimation is $2.25M, with a low revenue estimation of $0.00, and a high estimation of $4.00M.
Fulcrum Therapeutics's previous earnings date was Aug 10, 2021 for its fiscal quarter ended Jun 30, 2021.
FULC's earnings per share (EPS) was $-0.60, beating the consensus analysts forecast of $-0.65 by 8.10%.
The EPS was lower than the previous fiscal quarter (Mar 2021) by 11.11%, and higher than the same period a year before (Jun 2020) by -9.09%.
Revenues were $4.38M, better than the forecast of $1.60M by 173.81%, down by -8.52% from the previous quarter , and up by 119.05% from the same period last year.
The company reported a net income of $-19.65M.Free cash flow for the quarter was $-18.39M , compared to $-16.49M last quarter and $-14.33M a year before.
FULC ended the quarter with $469.00K in total debt, an increase of 11625.00% compared to the previous quarter, and an increase of 990.70% compared to the same quarter a year before.
Fulcrum Therapeutics's previous annual earnings date was Mar 4, 2021 for its fiscal year ended Dec 31, 2020.
FULC's earnings per share (EPS) was $-2.80, beating the consensus analysts forecast of $-2.88 by -2.78% , and lower than the previous year's EPS (Dec 2019) by 17.15%.
Revenues were $8.82M.
The company reported a net income of $-70.82M.
Fulcrum Therapeutics reported a free cash flow of $-55.00M for its fiscal year, compared to $-40.34M a year ago.
The company ended the fiscal year with $17.00K in total debt, a decrease of -66.00% compared to the previous year.
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.